The New Zealand Motor Neurone Disease Registry

Kerry Walker, Registry Curator



The Why

 September 2015 – First Walk 2 D'Feet MND 50% of funds raised → research

Patient Registries

- Collate all data in one place
- Attract research
- Access to participants
- Collaboration with international registries



In the beginning...

- First conceived Nov 2016
- Launched 22 May 2017



Consenting Dr Claire Reilly First Registry participant

Beth Watson Former MND NZ President



Prof Paul Talman Australian MND Registry





The How


Registry is a research study

- allows collection of data
- ethics
- based at ADHB

Recruitment Consent Clinical Info AMNDR



The How





Registry Demographics

163 active participants





Publications



Contents lists available at ScienceDirect

Journal of Clinical Neuroscience

journal homepage: www.elsevier.com/locate/jocn



Clinical study

Establishment and 12-month progress of the New Zealand Motor Neurone Disease Registry

Kerry L. Walker ^{a,*}, Miriam J. Rodrigues ^a, Beth Watson ^b, Claire Reilly ^b, Emma L. Scotter ^c, Heather Brunton ^d, Janet Turnbull ^e, Richard H. Roxburgh ^{a,f}

ARTICLE INFO

Article history:

Received 11 October 2018 Accepted 11 November 2018 Available online xxxx

Keywords: Epidemiology Patient registry Motor neuron disease

ABSTRACT

There are only limited treatments currently available for Motor Neurone Disease, each with modest benefits. However, there is a large amount of research and drug discovery currently underway worldwide. The New Zealand Motor Neurone Disease Registry was established in 2017 to facilitate participation in research and clinical trials, and to aid researchers in planning and recruitment. The NZ MND Registry is an opt in patient registry which collects demographic, contact and clinical data for those who choose to enrol. We report anonymised aggregated data from the first year's enrolment.

12th July 2018, there were 142 participants enrolled in the NZ MND Registry. Participant sex distribution reflects the demographics reported worldwide, but ethnicity is divergent from what is seen in New Zealand overall, with an over-representation of people who identify as New Zealand European. 85.5% of participants are diagnosed with sporadic MND and 6.1% with familial MND. The remainder were participants who have not been diagnosed but have a family history, or positive genetic test for a MND-causing



^a Department of Neurology, Auckland City Hospital, Private Bag 92024, Auckland 1142, New Zealand

^b Motor Neurone Disease New Zealand, PO Box 24-036, Royal Oak, Auckland 1345, New Zealand

Department of Pharmacology and Clinical Pharmacology, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland 1023, New Zealand

^d Department of Neurology, Christchurch Hospital, Private Bag 4710, Christchurch 8140, New Zealand

e Palliative Care Service, Wellington Hospital, Private Bag 7902, Wellington 6242, New Zealand

Centre for Brain Research, Neurogenetics Research Clinic, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland 1023, New Zealand

Research Studies

Enrolled

- Swallowing Skill Training
- Thought-assistive technology
- Stigma in MND
- Dr Scotter's genetic research

Upcoming

- Blood-brain barrier using MRI
- Remote wheelchair assessment

"Thank you so much for helping us with finding our participants for this study, it wouldn't be possible without you :)"

- Thought-Wired

Potential Studies

Enquiries from pharmaceutical companies



Registry Development

The role of a patient registry evolves along the pathway of drug development

Preclinical Development

Clinical Trials

Regulatory Approval

Commercial

- 1. Advancing disease understanding in the absence of treatment
- 2. Understanding real-world clinical practice, developing disease monitoring guidelines
- 3. Connecting patients, clinicians and researchers
- 4. Identifying patients for clinical trials
- 5. Informing clinical trial eligibility criteria
 - 6. Pooling nontreatment data
- 7. Commitment to post-marketing
- 8. Providing additional data supportive of trial findings
- 9. Data collection to support expansion of drug indication 10. Advancing the understanding of treatment response

The Bogard Model of the changing roles of a rare disease patient registry

Rodrigues MJ et al. 2017



Thank you

Please get in touch

Email: mndregistry@adhb.govt.nz

Phone: 0800 MND Registry or 027 561 7332

Visit: https://mnd.org.nz/registry/

